Lara Goldstein - Spark Newswire

2 minute read

EXCLUSIVE: atai’s Phase 1 Synthetic DMT-Based Drug Clinical Trial Begins Patient Dosing

October 5, 7:00 AM

Clinical-stage biopharma company atai Life Sciences N.V. (NASDAQ: ATAI) has commenced dosing volunteers for its ongoing Phase 1 clinical study investigating its proprietary DMT-based VLS-01 for treatment-resistant depression (TRD).

ATAI

2 minute read

Justice Dept Grants $1M To Non-Profits To Help Stem Teen Mental Health Issues & School Violence

By Lara Goldstein

October 3, 6:10 PM

A silent epidemic is moving across the country. Each year, from one in five children in the U.S., show signs or symptoms of a mental health disorder, be it depression, anxiety or substance abuse.

RVLWF

3 minute read

Can Ketamine Treat Alcohol Addiction? This Is How Therapy Actually Functions

By Lara Goldstein

October 3, 12:10 PM

(Part two of a four-part series, see part one here)

AWKNF

4 minute read

Psyched: Autopsy Reveals Death By Ketamine, LSD-Like Drugs Without Hallucinations, DEA & Right To Try Psilocybin

By Lara Goldstein

September 30, 4:15 PM

Amended Autopsy Confirms Elijah McClain Died From Ketamine Injected By Paramedics Called By Cops

ATAI

2 minute read

Irwin Naturals Acquires Ketamine Media, Nation’s Leading Platform For Ketamine Clinics

By Lara Goldstein

September 30, 3:07 PM

Irwin Naturals Inc. (OTC: IWINF) is expanding its efforts in offering ketamine-assisted therapy to those in need.

IWINF

1 minute read

International Magic Mushrooms: Where Are They Produced And Where Are They Headed?

By Lara Goldstein

September 29, 3:50 PM

Psyence Group Inc.

PSYGF

1 minute read

Magic Mushroom In A Pill? New Microdose Plans Enter Clinical Studies: Here’s What Scientists Want To Learn

By Lara Goldstein

September 29, 2:36 PM

Nova Mentis Life Science Corp. (OTCQB: NMLSF), a biotech company focused on creating psilocybin-based therapeutics produced 1.5 mg psilocybin microdose capsules compliant with the chemistry, manufacturing and controls (CMC) published guidelines.

NMLSF

1 minute read

Psychedelics Capital Markets: Silo Pharma’s IPO, $5M Common Stock Offering

By Lara Goldstein

September 27, 6:01 PM

Developmental-stage biopharma company Silo Pharma Inc. (NASDAQ: SILO) announced the pricing of an underwritten public offering of 1,000,000 shares of its common stock at $5.00 per share, to begin trading on NASDAQ on Tuesday, September 27, 2022 under trading symbol “SILO.”

SILO

2 minute read

Psychedelics Companies And IPs: An Extended Patent Application To Protect Multiple LSD Derivatives

By Lara Goldstein

September 27, 5:57 PM

In parallel with working towards discovering and advancing therapeutic psychedelics, biopharma companies are continuously protecting their findings.

BETRF

2 minute read

Cybin Acquires Exclusive License To Mindset Pharma’s Tryptamine Compounds Family

By Lara Goldstein

September 27, 2:20 PM

Through its wholly-owned subsidiary, Cybin IRL Limited, Canadian-based psychedelics biotech Cybin Inc. (NYSE AMERICAN: CYBN) signed an agreement with next-gen psychedelics producer Mindset Pharma Inc.

CYBN